IONS news

Roche halted the Phase 3 IMAgINATION study due to positive results from Ionis Pharmaceuticals, where sefaxersen showed a clinically meaningful 43.1% reduction in proteinuria, a key kidney repair indicator, relative to placebo at 37 weeks. This achievement is a significant milestone for targeted trea…

The company announced that partner Roche's trial met its primary endpoint, offering a treatment option that may prevent kidney failure.

Novartis reported the Lp(a)HORIZON Phase 3 trial for competitor pelacarsen did not meet its primary endpoint of reducing cardiovascular events, while Ionis continues independent commercialization efforts.

The FDA has approved Ionis Pharmaceuticals' ZANVASTRO, the first disease-modifying therapy for Alexander disease. This approval marks Ionis' second independent launch of the year and includes a Priority Review Voucher.

Ionis exceeded revenue expectations with a 56% increase compared to the prior year, driven by commercial success and partnerships. The company remains on track to achieve 2026 guidance and reported a strong cash balance of $2.1 billion.

The CARDIO-TTRansform trial for eplontersen did not meet its primary cardiovascular endpoint vs. placebo, though a positive signal was seen in monotherapy. The missed readout presents a setback for the drug's add-on therapy strategy, potentially weighing on the stock despite positive pipeline outloo…

Ionis Pharmaceuticals announced the FDA approval of olezarsen (Tryngolza), a new treatment for severe hypertriglyceridemia. This marks the company's first independent commercial launch in a prevalent disease and is designed to significantly reduce acute pancreatitis risk in patients.

Ionis Pharmaceuticals announced the appointment of Ludwig Hantson, Ph.D., a veteran biopharma executive with 30+ years of experience including CEO roles at Alexion and Baxalta, to its Board of Directors effective immediately. The appointment strengthens board expertise as Ionis prepares for multiple…

GSK announced positive Phase 3 pivotal data for bepirovirsen, Ionis's antisense oligonucleotide, showing a 19% functional cure rate versus 0% with standard of care in chronic hepatitis B patients. The results represent significant commercial potential for Ionis through its partnership with GSK in a …